Incyte Corp’s recently made public that its Officer SHEILA DENTON acquired Company’s shares for reported $45310.0 on Aug 04 ’25. In the deal valued at $75.77 per share,598 shares were bought.
Then, Stein Steven H sold 3,706 shares, generating $251,786 in total proceeds. Upon selling the shares at $67.94, the EVP & Chief Medical Officer now owns 102,886 shares.
Before that, STEVEN STEIN bought 3,706 shares. Incyte Corp shares valued at $251,786 were divested by the Officer at a price of $67.94 per share.
Barclays initiated its Incyte Corp [INCY] rating to an Overweight in a research note published on August 01, 2025; the price target was $90. A number of analysts have revised their coverage, including Stifel’s analysts, who increased its forecast for the stock in mid June from “a Hold” to “a Buy”. William Blair also remained covering INCY and has decreased its forecast on March 18, 2025 with a “Mkt perform” recommendation from previously “an Outperform” rating. Guggenheim revised its rating on March 18, 2025. It rated INCY as “a Neutral” which previously was an “a Buy”.
Price Performance Review of INCY
On Monday, Incyte Corp [NASDAQ:INCY] saw its stock jump 3.24% to $78.04. Over the last five days, the stock has gained 11.23%. Incyte Corp shares have risen nearly 19.93% since the year began. Nevertheless, the stocks have risen 12.99% over the past one year.
How much short interest is there in Incyte Corp?
A steep rise in short interest was recorded in Incyte Corp stocks on 2025-07-15, dropping by -1.07 million shares to a total of 7.12 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 8.19 million shares. There was a decline of -14.99%, which implies that there is a negative sentiment for the stock.
